Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

Abstract: A computer-implemented method of processing digital image data. The method includes: determining, by an encoder configured to map a first digital image to an extended latent space associated with a generator of a generative adversarial network, GAN, system, a noise prediction associated with the first digital image, determining, by the generator of the GAN system, at least one further digital image based on the noise prediction associated with the first digital image and a plurality of latent variables associated with the extended latent space.

Abstract: A computer-implemented method for training an encoder. The encoder is configured for determining a latent representation of an image. Training the encoder includes: determining a latent representation and a noise image by providing a training image to the encoder, wherein the encoder is configured for determining a latent representation and a noise image for a provided image; masking out parts of the noise image, thereby determining a masked noise image; determining a predicted image by providing the latent representation and the masked noise image to a generator of a generative adversarial network; training the encoder by adapting parameters of the encoder based on a loss value, wherein the loss value characterizes a difference between the predicted image and the training image.

Abstract: Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.

Abstract: The present disclosure provides proteins, nucleic acids, vectors, and host molecules useful for the production of compounds of interest, and methods for their use.